Bioventus Finds Alternative Option to Acquire CartiHeal

Where there’s a will, there’s M&A. This is the case for Bioventus, as the company has amended the structure of its CartiHeal acquisition.

The amendment comes about a month after the company withdrew the offering of senior notes to pay for CartiHeal, citing current market conditions and said it would explore alternative financing options for the $315 million upfront payment.